MAP2K7 and melanoma: Unlike melanomas harboring BRAF mutations, which are highly sensitive to MAPK inhibition (BRAF and MEK inhibitors; BRAFi, MEKi), BRAFi treatment of melanomas harboring wild-type BRAF (including NRAS-mutant) activates MEK/ERK and increases melanoma growth [4].